Document is current
Any future updates will be listed below
-
Authors
Leshno, Ari http://orcid.org/0000-0002-8717-1659
Tsamis, Emmanouil
Harizman, Noga
De Moraes, Carlos Gustavo
La Bruna, Sol
Rai, Anvit
Garg-Shukla, Aakriti http://orcid.org/0000-0002-0765-8337
Cioffi, George A.
Wang, Qing
Liebmann, Jeffrey M. http://orcid.org/0000-0002-5663-0533
Hood, Donald C.
- License Information
-
More Information
Article History
Received: 9 November 2022
Revised: 12 June 2023
Accepted: 19 June 2023
First Online: 30 June 2023
Competing interests
: DCH: Topcon, Inc. (F, R); Heidelberg Engineering (F, R); Novartis, Inc. (F, R). CGDM: Carl Zeiss Meditec, Inc. (C); Novartis (C); Heidelberg Engineering (R); Topcon (F); Galimedix (C); Perfuse Therapeutics (C); Ora Clinical, Inc. (E) JML: Carl Zeiss Meditech, Inc. (R); Heidelberg Engineering (R).
